Primex Pharmaceuticals
Primex Pharmaceuticals is an innovative and fast-growing company spearheading a new pharmaceutical business model, in operation since early 2008. It has a global reach through regional marketing and distribution.
World-wide distribution
Primex supplies high-quality medicines to healthcare institutions and professionals around the world, from the EU to Asia, and from Latin America to the Middle East. Primex products are available in a total of 39 countries world-wide, while its distribution reaches a population of nearly one billion people.
High-quality medicines
Primex is specialized in anesthesia, cardiology, oncology and intensive care, and constantly expanding. Primex markets world class brands, such as Dobuject and Recofol, all over the world. Both are the most advanced versions in their categories.
Primex Pharmaceuticals is an innovative and fast-growing company spearheading a new pharmaceutical business model, in operation since early 2008. It has a global reach through regional marketing and distribution.
World-wide distribution
Primex supplies high-quality medicines to healthcare institutions and professionals around the world, from the EU to Asia, and from Latin America to the Middle East. Primex products are available in a total of 39 countries world-wide, while its distribution reaches a population of nearly one billion people.
High-quality medicines
Primex is specialized in anesthesia, cardiology, oncology and intensive care, and constantly expanding. Primex markets world class brands, such as Dobuject and Recofol, all over the world. Both are the most advanced versions in their categories.
Location: Italy
Employees: 11-50
Phone: +41 41 720 20 00
Founded date: 2010
Investors 3
| Date | Name | Website |
| - | Innovestor | innovestor... |
| 01.10.2021 | Tesi | tesi.fi |
| - | Bocap | bocap.fi |
Mentions in press and media 1
| Date | Title | Description |
| 13.09.2018 | Bocap's Portfolio Company Primex Pharmaceuticals Has Received Marketing Authorization (MA) in the EU for OZALIN® | Bocap’s first fund’s portfolio company Primex Pharmaceuticals AG announces it has received marketing authorization (MA) in the EU for OZALIN® (ADV6209) for children from 6 months to 17 years for moderate sedation before therapeutic or diagn... |